Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00183235 · ClinicalTrials.gov registry record · Phase 2
Aripiprazole Effects on Alcohol Reactivity and Consumption
A Phase 2 study of Alcohol Dependence, sponsored by Medical University of South Carolina.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT00183235: Completed Phase 2 study of Alcohol Dependence, sponsored by Medical University of South Carolina.
NCT00183235 is a Phase 2 study of Alcohol Dependence that has completed, run by Medical University of South Carolina. The registered enrollment target is 30 participants, below the 313-participant average among 43 other Alcohol Dependence trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00183235, a Phase 2 study of Alcohol Dependence, has completed, sponsored by Medical University of South Carolina.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine whether aripiprazole (marketed dopamine stabilizer) is effective in reducing of alcohol craving compared to placebo.
Conditions Studied
Interventions
- DRUG aripiprazole (up to 15 mg/day) for 8 days
Study Locations (1)
South Carolina
- Center for Drug and Alcohol Programs, Medical University of South Carolina - Charleston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2005-06 |
| Est. Completion | 2006-02 |
| Phase | Phase 2 |
What the finished NCT00183235 record still lists
NCT00183235 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 313-participant average among 43 other Alcohol Dependence trials with a reported enrollment target (90% lower).
The record links to 1 condition, with Alcohol Dependence appearing as the primary indexed condition, and to 1 intervention - of which aripiprazole (up to 15 mg/day) for 8 days is the first listed.
NCT00183235 reports a single indexed study location in South Carolina.
Frequently Asked Questions
What is clinical trial NCT00183235 about?
NCT00183235 is a clinical study titled "Aripiprazole Effects on Alcohol Reactivity and Consumption". The purpose of this study is to determine whether aripiprazole (marketed dopamine stabilizer) is effective in reducing of alcohol craving compared to placebo.
What is the current status of trial NCT00183235?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2005-06. Estimated completion is 2006-02.
What conditions does trial NCT00183235 study?
This clinical trial studies the following conditions: Alcohol Dependence.
What interventions are being tested in trial NCT00183235?
The interventions under investigation include: aripiprazole (up to 15 mg/day) for 8 days (DRUG).
Who is sponsoring clinical trial NCT00183235?
This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00183235 being conducted?
This trial has 1 study location across South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alcohol Dependence
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00183235's enrollment target sits among peer trials
30 39th of 43 higher than 5 of 43 other Alcohol Dependence trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alcohol Dependence trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Psilocybin or Ketamine for Alcohol Use Disorder: An Active Comparator Trial
RECRUITING · Phase 2
-
Gabapentin Treatment of Alcohol Dependence
COMPLETED · Phase 2
-
The MEADOW PROJECT (Mending the Effects of Alcohol and Depression on Women) and The Bridge Program (Connecting Recovery Treatment and Behavioral Health)
COMPLETED · Phase 2
-
Neuromodulation of Trauma Memories in PTSD & Alcohol Dependence
COMPLETED · Phase 2
-
A Therapeutic Workplace for Alcohol Dependence
COMPLETED · Phase 2
-
Modification of Cognitive Processing Therapy (CPT-C) for PTSD and Alcohol Dependence
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia